SCHOTT Pharma AG & Co KGaA

EVERIC® freeze delivers an improved strength for deep cold storage applications, reducing the risk of breakage. This is based on: - The usage of FIOLAX® OS (optimized strength) - a glass tubing with an improved scratch & fissure specification, without changing its chemical composition - An optimized conv...

Sterile integrity is indispensable in aseptic fill-and-finish operations. Pharmaceutical companies pay highest attention to mitigating the risks of contaminated batches, which lead to recalls, high costs and reputation loss. Ensuring the sterility of all components when entering the aseptic filling core is...

Schott Ag offers a wide range of products which includes ampoules. It is the most common packaging solutions worldwide, and they offer a special benefit,the medication is in contact with glass only and the packaging is 100% tamper-proof,made of clear or amber schott fiolax® glass tubes (borosilicate glass ...

Schott Ag offers a wide range of products which includes cartridges. It is a leading supplier of pen cartridges and special solutions like double chamber cartridges in the range of 1 ml up to 10 ml volume,cartridges are available for pen injection systems, for anti-diabetes therapy such as modern and human...

Schott Ag offers a wide range of products which includes glass prefillable syringes – syriqtm. It belongs to Syringes category. It is high-quality syringe barrels are produced on fully automated, high-speed precision forming lines. Rigorous product inspection and strict process control is ensured by s...

Schott Ag offers a wide range of pharmaceutical packaging products which includes polymer prefillable syringes – schott toppac®. It belongs to Syringes category. It is prefillable syringes are made of coc (cyclic olefin copolymer), the ready-to-fill syringes are break resistant, light weight, and tran...

Schott Ag offers a wide range of products which includes vials. It offers a broad range of glass vials from 1 ml to 100 ml with different neck finish designs (crimp neck or screw neck), with european or american blowback or without blowback.Contact us for more information.

Sustainability is of paramount importance in the pharmaceutical industry. See how a recent partnership between CPHI and SCHOTT Pharma has helped to highlight and accelerate their sustainability journey to reach global goals. 

The pharmaceutical sector is dedicated to caring for and improving the well-being of others, yet we often overlook the well-being of those working within the industry. This session offers a break from the hustle and bustle of the show floor, providing an opportunity to explore key areas for personal and professional growth. Learn strategies to manage stress and transform your life for the better. Join us to discover how to prioritize your well-being in a demanding field.

Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target

Strengthen your supply chain! Craft guiding principles for diversity and action-oriented collaboration at our "Credos for Powerful Partnerships Supplier Diversity: Building a strong network of diverse suppliers fosters innovation and resilience. Action Orientation in Supplier-Customer Relationship: How to work with suppliers to create impact and change? And why data is important, but yet no reason to wait before taking action. Importance of joint understanding: An impactful engagement of suppliers requires a mature understanding on both sides. This presentation will report on some outcomes of a CPHI accompanying workshop on “Sustainable Procurement” on what is needed to speak the right language and drive change along the supply chain.

This session will delve into the major challenges the pharmaceutical industry encounters in managing Scope 3 emissions, which make up the bulk of its carbon footprint. It will examine why these emissions are especially difficult to control due to the complexities within the value chain. Additionally, the session will emphasize the potential of zero-carbon molecules as sustainable building blocks for pharmaceutical applications, offering a promising route to reducing Scope 3 emissions. The discussion will also highlight the crucial need for industry-wide collaboration—from renewable energy and electrolysers to green hydrogen and partnerships across the supply chain, including raw material suppliers and manufacturers—in advancing innovation and decarbonization. By embracing new technologies and fostering cooperation, the industry can accelerate the integration of zero-carbon molecules into pharmaceutical production. The session will conclude with practical insights on how the pharmaceutical sector can reduce its environmental impact and pursue a sustainable future in alignment with global decarbonization goals.

The absence of a compelling business case is a key barrier to net-zero transformation of the pharma ecosystem. This panel discussion focusses on how this barrier can be overcome by adjusting the business model and organizational concepts. Join this session and get inspiration on how to translate environmental initiatives into financial benefits and how coverage of the extra cost can happen across the ecosystem to realize true change of our industry.

The triple bottom line demands that people, planet, and profit converge. Profit remains a central focus of enterprises and often is in conflict with the others two pillars. Finding the right business model is crucial to enable sustainability efforts to become a business instead of a cost case. This session will focus on best-practice examples from outside the pharma industry to inspire on how sustainability efforts can be integrated in a successful business strategy. Winning based on sustainability -Learn from a successful example outside pharma, how a focus on sustainability can be successfully applied to strengthen an organization and to win business Sustainable business models – Learn from latest research on business model innovation and example cases: Which business model concepts can support a successful transformation to win business based on sustainability

The Science-Based Targets initiative (SBTi) translates compliance to the limitation of global warming to 1.5°C as per the Paris Agreement to the requirement to decarbonise Scope 1 and 2 emissions by 90%. This necessitates not just an adjustment of current operational strategies, but a fundamental rethinking. Since the limitation of global warming also relies on an intact biodiversity and resilient nature, future concepts require an equal emphasis on the avoidance of pollution. Discover best-practice examples and get inspired about how to rethink your manufacturing processes for a sustainable future. Green chemistry: What is green chemistry and how can those principles be applied to different stages of the manufacturing process Defossilisation: How can we make carbon a resource instead of a problem and keep carbon in the loop instead of sending it to the atmosphere. Green facilities: How to organise manufacturing

Today’s practice of single-use plastic packaging in pharma industry is a waste and emission driver consuming finite resources. As of today, virgin material is applied to ensure patient safety resulting in large quantities of waste. Three pharma pioneers addressed this issue led by the question: How to overcome the need for virgin material, and apply recycled content in a pharma-compliant way? This session will focus on - the risks and opportunities in applying recycled material in pharma, - an approach to close the loop for plastic packaging in a pharma-compliant way, - the results of pilot operations at ton scale.

Green chemistry and engineering offer a path to sustainable processes, materials, and products that align with the UN Sustainable Development Goals. In pharmaceuticals, a significant portion of the environmental impact, especially carbon footprint, comes from producing Active Pharmaceutical Ingredients (APIs). Successful adoption of green chemistry principles and metrics is shown to significantly reduce this impact resulting in tangible triple-bottom line benefits. The ACS Green Chemistry Institute (GCI) has a unique collaboration with the pharma industry and its supply chain to change the way chemistry is done by catalyzing tangible green chemistry and engineering innovations that translate into more efficient, cost-effective, and sustainable chemical processes. Join us to learn: - Why API chemistry should be the cornerstone of sustainability strategies - What green chemistry metrics and tools are available to optimize processes - How the ACS GCI Pharmaceutical Roundtable encourages innovation and recognizes outstanding achievements in the global adoption of green chemistry

Join us as we explore the role sustainability professionals within organizations to shape and drive the sustainability ambition and agenda. Discover how sustainability professionals—from leaders to cross-functional teams—are shaping a culture of environmental responsibility, streamlining actions towards net zero emissions and driving a culture for sustainable business practices. Hear insights from industry experts about how these roles are transforming companies into key players in the pursuit of a greener, more sustainable future.

The world’s leading pharmaceutical and healthcare companies are collaborating to reduce scope 3 emissions. Energize, a first-of-its-kind program, is designed to accelerate the adoption of renewable electricity aimed to decarbonize the pharmaceutical and healthcare global supply chain. In partnership with Schneider Electric, the 21+ Energize sponsors are removing barriers to entry to the renewable electricity market by providing critical access to education and support. This award-winning initiative has already achieved significant emissions reductions and continues to grow. Join us to learn about how Energize works, what the program has achieved so far, and how suppliers can participate in this program at no cost to them.

Creating impact requires clarity of the problem you intend to solve. Join us for a focused session exploring the emission drivers behind different drug delivery methods like tablets, inhalers, and injectables. Harmonized parallel assessment helps you to understand commonalities and differences on the path towards sustainable products: Tablets Inhalers Injectables

Join our opening keynote session as we delve into the understanding of what is behind the buzz word of sustainability in the context of the pharmaceutical industry. In an interactive manner, we’ll assess what our sustainability priorities are. and compare the state of sustainability integration in the pharma industry to other industries. s. This dynamic session will therefore equip you with insight on where we stand as an industry and what are our specific challenges and opportunities to promote impact to sustainable development. Be part of the conversation shaping the sustainable future of pharma

In pharmaceutical manufacturing, operational efficiency is crucial for meeting production targets while ensuring product quality and reducing manufacturing cost. One impactful strategy is increasing the number of cavities per nest for prefilable polymer syringes. This enhancement maximizes conveyor space utilization, streamlines production processes, and supports sustainability objectives by minimizing material and energy consumption per unit. Join us to discover how this simple yet impactful adjustment can lead to significant improvements in efficiency, cost-effectiveness, and environmental responsibility for pharmaceutical manufacturers.

Diversity and inclusion can be fostered in different spheres of influence within the pharma industry and with varying results. This inspiring session aims to shed light on many of these critical points of view. Join us to gain firsthand insights from our distinguished panel of experienced leaders – (CEOs, CTOs, and CSOs). You’ll get to explore what transformative strategies and initiatives can be applied within your company to foster and increase diversity equity and inclusion. This session will equip you with the knowledge and tools needed to contribute to positive change in the corporate world, creating a more inclusive space for everyone in your company. This session will share valuable knowledge and provide you with some useful skills and advice on how to begin contributing to positive change in your company. Creating an opportunity to begin engineering more inclusive spaces for everyone working in pharma is an important first step.

The presentation will highlight how we can use bio attributed polymers to reduce the carbon footprint without compromising product safety. With certified bio circular raw materials polymers can be produced to enable our customers to reduce their carbon footprint.

The proposed PPWR will overhaul everything about the way packaging is designed and used in the EU and is likely to influence global policy for many years. With tight targets for inclusion of recycled content for all industries, including pharmaceutical packaging from 2030, the industry is looking for safe ways to recirculate materials into contact sensitive applications. Regulators are exploring ways to increase the amount of high quality mechanically recycled material available, but also at the role of chemical recycling in expanding opportunities for circularity. We will explore the current regulatory debate looking at how to incorporate this new technology into the legislative framework.

Learnings and experiences with establishing Takeback and Recycling systems for medical devices will be presented during this session, with a focus on regulatory, logistical and technical challenges and how to overcome them. Frode will also zoom in on the value of recycling and how to use the learnings to shape a different future addressing the way we use our resources and creating business around recycling.

After years of investment in research & development, pharmaceutical companies have brought to the market a growing number of new therapies based on mRNA or viral vector technology, which require storage at freezing temperatures. Deep cold storage poses great challenges to the primary packaging container. This session will be dedicated to exploring the challenges and latest developments in ensuring the integrity and stability of pharmaceuticals drugs stored at deep cold temperatures. The attendees will have the chance to learn about the benefits of the latest SCHOTT Pharma innovation: EVERIC® freeze, a glass vial, with optimized strength for deep cold applications down to -80°C.

Meet industry sustainability experts in an informal setup for an open discussion on what matters the most for you as part of the Pharma industry. What are your current sustainability planning issues and how could you solve them? What could be your next steps and with whom do you need to collaborate to reach your sustainability goals? Representatives of BioPhorum, PSCI, Nelipak, and Informa will be available to guide you to: start setting up your sustainability strategy & focus areas get started with your action plans connect you with the right partners Through our community, purposeful partnerships and meaningful content, you will get ideas and support needed to put sustainability at the heart of your business.

Let’s play it green: Realizing a decarbonized supply chain in parenteral drug administration Pharmaceutical companies are under significant pressure to address climate change and implement sustainable practices in their operations. They face the imperative of meeting commitments and stringent targets for scientific advancements and carbon reduction. A significant portion of emissions is generated throughout the drug manufacturing supply chain. This presentation presents the steps necessary for achieving a decarbonized supply chain for parenteral drug administration. Additionally, the presentation will highlight the constraints individual companies face in driving change and emphasize the role of cross-company initiatives, such as the Alliance to Zero, in creating synergies across the industry.

Towards a circular economy within the healthcare sector: What are the challenges? There is a fast-increasing awareness regarding the high environmental impact of our healthcare sector and the consequences it has. There is an urgent need for collaborative initiatives to reduce the environmental impact of our current and future healthcare practices. One way to approach this is the application of Circular Economy Strategies on Medical devices. During my presentation I will present Examples of collaborative Circular Economy initiatives by Industry and Hospitals.

We are all willing to have sustainable products for the future. The open question is: how do we get there? This sustainability conference will start with inspiring experiences from sustainable healthcare initiatives. Presentations the focus on potential pathways and drivers for decarbonization of drug containment and delivery systems. The program gets complemented by discussion of what blocks our ecosystem from transforming and how those barriers can be overcome.

In this presentation, attendees will learn about the profound impact of pre-sterilized and pre-washed vials, commonly known as ready-to-use (RTU) vials, on enhancing patient safety. The speech emphasizes how RTU vials contribute to a reduction in contamination risks, thereby decreasing the potential for product recalls and ultimately infections. By eliminating the need for laborious process development, validation, and quality control, RTU vials streamline processes by implementing highly standardized and effective sterilization and washing procedures directly into the product. Thus, saving valuable time and resources for pharmaceutical companies. Based on case studies, the healthcare benefits of implementing RTU vials in various pharmaceutical operations will be illustrated. Attendees will gain insights into how this approach not only elevates product quality but also plays a pivotal role in upholding patient safety standards.

After years of investment in R&D, pharmaceutical companies have brought to the market a growing number of new therapies based on mRNA or viral vector technology, which require storage at freezing temperatures. Deep cold storage poses great challenges to the primary packaging container. This session will be dedicated to exploring the challenges and latest developments in ensuring the integrity and stability of pharmaceuticals drugs stored at deep cold temperatures. The attendees will have the chance to learn about the benefits of two SCHOTT Pharma innovations: TOPPAC® freeze, a polymer syringe suitable for deep cold storage down to -100°C, and EVERIC® freeze, a glass vial, with optimized strength for deep cold applications down to -80°C.

New therapeutic treatments or prophylactic vaccines rely on more complicated drug formulations, often based on biologics. These drugs are highly sensitive and might require low temperature storage to keep them stable over shelf life. These extreme cold supply chain processes, something up to -80°C, provide a new challenge to pre-fillable syringes. In this presentation we will show you scientifically based argumentations and results to help you to select the right pre-fillable syringe for your low temperature application.

In this webinar, originally broadcast as part of the Pharmapack Europe show, Dr. Robert Lindner, Global Product Manager RTU Vials, SCHOTT AG will discuss how sterile integrity is indispensable in aseptic fill-and-finish operations. Pharmaceutical companies pay highest attention to producing high quality drugs and safekeeping their efficacy during fill-and-Finish and beyond. The risks of contaminated batches leads to recalls, high costs, reputation loss and in the worst scenario may harm patients’ wellbeing. Hence, it is the pharma company’s obligation to ensure the sterility of all components when entering the aseptic filling core - which is possible, yet cumbersome with the RTU solutions that are currently available within the industry.